Neovir® (Neovir®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceOxodihydroacridinylacetate sodiumOxodihydroacridinylacetate sodium
Similar drugsTo uncover
  • Neovir®
    solution w / m 
    FARMSINTEZ, PAO     Russia
    • Dosage form: & nbspsolution for intramuscular injection
    Composition:

    1 ml of the solution contains:

    Active ingredient: sodium oxo-dihydroacridinylacetate (Neovir®) 125 mg;

    Excipients: sodium citrate 2.5 mg, acid citric monohydrate 0.5-1.5 mg (up to pH 7.5-8.3), water for injection up to 1 ml.

    Description:Transparent liquid is greenish-yellow in color.
    Pharmacotherapeutic group:Immunostimulating agent
    ATX: & nbsp

    L.03.A.X   Other immunostimulants

    Pharmacodynamics:

    The drug has an antiviral effect against DNA and RNA genomic viruses. Has a pronounced anti-Chlamydial effect.

    Neovir ® causes a rapid increase in the titers of endogenous interferons a, p, y, in particular interferon a. Introduction 250 mg of neovir ® intramuscularly for serum concentrations of interferon is equivalent to the introduction of 6-9 million ME recombinant interferon a. The peak of interferon activity in the blood is observed after 1.5-2 hours and persists for 16-20 hours after the administration of Neovir ®. As a result, the body induces a cascade of immune reactions aimed at the destruction and elimination of pathogens and cells affected by them.Cells - producers of interferon acquire the ability for enhanced production of interferon in response to the repeated induction caused by the pathological agent. This property persists for a long time after drug discontinuation.

    Immunomodulating effect is due to the ability of Neovir® to activate stem hematopoietic cells, to normalize the balance of T-lymphocyte subpopulations, to stimulate the effector links of the immune system. Neovir ® has a pronounced stimulating effect on the functional activity of macrophages and polymorphonuclear leukocytes, enhancing their migration and phagocytic activity.

    Neovir ® corrects tissue growth: activates NKcells, strengthens all forms of cytotoxicity, positively influences the restoration of cell adhesiveness, inhibits their proliferative and metastatic activity.

    Pharmacokinetics:

    With intramuscular injection, the bioavailability of neovir ® is more than 90%. After the administration of 100-500 mg of neovir, the maximum plasma concentration is reached after 15-30 minutes and is 8.3 μg / ml. After 5 hours, only small amounts of neovir ® are detected, after 6 hours Neovir ® in the blood plasma is not detected.

    Neovir ® is excreted from the body in an unchanged form by the kidneys, without being metabolized, with a half-life of 1 hour.

    After 15-30 min after the introduction of neovir ® in the plasma begin to increase the titers of endogenous interferons, in particular, early interferon α. Two peaks of interferon a in plasma were detected: 70 IU / ml after 1.5-2 hours and 110 IU / ml after 8-10 hours, after which the content of interferon α begins to decrease. After 24 hours, the concentration of endogenous interferons remains sufficiently high, to the initial values ​​is returned 46-48 hours after administration.

    Indications:In the form of monotherapy or as part of complex therapy:

    - influenza and other acute respiratory viral diseases, including against the background of immunodeficiency states;

    - infections caused by the virus Herpes simplex, Varicella zoster, Herpes simplex genitalis, including those with impaired immune system;

    - cytomegalovirus infection in immunocompromised individuals;

    - radiation immunodeficiency;

    - HIV infection;

    - encephalitis and encephalomyelitis of viral etiology;

    - acute and chronic hepatitis B and C;

    - urethritis, epididymitis, prostatitis, cervicitis and salpingitis of chlamydial etiology;

    - venereal lymphogranuloma;

    - oncological diseases;

    - Multiple sclerosis;

    - Candidiasis lesions of the skin and mucous membranes;

    - papillomavirus infection.

    Prevention of influenza and other acute respiratory viral diseases.

    Contraindications:- Individual intolerance to the drug;

    - pronounced failure of kidney function (creatinine clearance less than 30 ml / min);

    - autoimmune diseases;

    - Pregnancy and lactation;

    - Children under 18 years.

    Carefully:

    Use with caution elderly patients.

    Pregnancy and lactation:

    The safety of Neovir ® during pregnancy and lactation is not known, therefore the drug is contraindicated for use during pregnancy and during breastfeeding.

    Dosing and Administration:

    The injection solution is administered intramuscularly, a single therapeutic dose is 250 mg (1 ampoule) or 4-6 mg per kg of body weight of the patient. If necessary, a single dose of Neovir ® can be increased to 500 mg.

    The course of treatment, if there is no specific indication, consists of 5-7 intramuscular injections of Neovir ® at a dose of 250 mg with an interval of 48 hours, the course dose depends on the clinical picture.Duration of the course is 8-12 days. A single prophylactic dose is 250 mg (1 ampoule) or 4-6 mg per kg of body weight. With prolonged use, the recommended interval between Neovir ® injections is 3-7 days.

    In HIV infection, Neovir ® for injection is used in combination with specific antiviral drugs. The course of treatment consists of 10 injections of 250 mg with an interval between injections of 48 hours. After the course, take a break for 2 months. It is possible to use repeated courses according to the indications.

    Side effects:

    In single cases, the appearance of an allergic reaction in the form of rashes on the skin. Possible subfebrile temperature, local rapidly passing pain in the place of administration of the drug. In case of poor tolerance or pain in the injection site, it is recommended to inject Neovir ® together with a solution of local anesthetic (2 ml of 0.25-0.5% procaine solution).

    Overdose:

    Cases of overdose Neovir ® is not described.

    Interaction:

    Physicochemical incompatibility and other types of undesirable interaction have not been identified.

    Effect on the ability to drive transp. cf. and fur:

    Information on the possible adverse effects of the drug on the performance of potentially hazardous activities,requiring special attention and quick reactions (driving and other vehicles, working with moving mechanisms, dispatcher and operator work, etc.) is not available.

    Form release / dosage:

    Solution for intramuscular injection, 250 mg / 2 ml.

    Packaging:

    In ampoules of light-protective glass 2 ml each; 3, 5 ampoules in a contoured cell pack of a polyvinyl chloride film; 1 contour pack with instructions for medical use in a pack of cardboard.

    Storage conditions:

    In the dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.

    Turbidity of Neovir ® solution to milk-white color indicates a violation of storage conditions and unfitness to use.

    Shelf life:

    5 years.

    Do not use after the expiration date indicated on the packaging.

    Terms of leave from pharmacies:On prescription
    Registration number:P N003311 / 01
    Date of registration:05.11.2009 / 03.07.2017
    Expiration Date:Unlimited
    The owner of the registration certificate:FARMSINTEZ, PAO FARMSINTEZ, PAO Russia
    Manufacturer: & nbsp
    Representation: & nbspFARMSINTEZ, PAO FARMSINTEZ, PAO Russia
    Information update date: & nbsp19.06.2018
    Illustrated instructions
      Instructions
      Up